Marrow morphology of chronic myelogenous leukemia in patients treated with imatinib mesylate (Gleevac, Sti-571): Correlation with cytogenetic response

被引：0
|
作者：
Racke, F
Allan, RW
Miller, C
Weir, EG
机构：
[1] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[2] St Agnes Hosp, Baltimore, MD USA
来源：
MODERN PATHOLOGY | 2005年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1148
引用
收藏
页码：248A / 248A
页数：1
相关论文
共 50 条
  • [21] Cytogenetic responses in chronic myeloid leukemia patients treated with imatinib mesylate
    Babameto-Laku, A.
    Mokin, V.
    Cikuli, M.
    Xhumari, P.
    CHROMOSOME RESEARCH, 2005, 13 : 158 - 158
  • [22] Primary gastrointestinal stromal tumor of the liver with lung metastases successfully treated with STI-571 (imatinib mesylate)
    De Chiara, A
    De Rosa, V
    Lastoria, S
    Franco, R
    Botti, G
    Iaffaioli, VR
    Apice, G
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2006, 11 : 498 - 501
  • [23] Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy
    Kvasnicka, HM
    Thiele, J
    Staib, P
    Schmitt-Graeff, A
    Griesshammer, M
    Klose, J
    Engels, K
    Kriener, S
    BLOOD, 2004, 103 (09) : 3549 - 3551
  • [24] Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)
    Fischer, T
    Reifenrath, C
    Hess, GR
    Corsetti, MT
    Kreil, S
    Beck, J
    Meinhardt, P
    Beltrami, G
    Schuch, B
    Gschaidmeier, H
    Hehlmann, R
    Hochhaus, A
    Carella, A
    Huber, C
    LEUKEMIA, 2002, 16 (07) : 1220 - 1228
  • [25] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    Kantarjian, H
    Sawyers, C
    Hochhaus, A
    Guilhot, F
    Schiffer, C
    Gambacorti-Passerini, C
    Niederwieser, D
    Resta, D
    Capdeville, R
    Zoellner, U
    Talpaz, M
    Druker, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09): : 645 - 652
  • [26] Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience
    Braziel, RM
    Launder, TM
    Druker, BJ
    Olson, SB
    Magenis, RE
    Mauro, MJ
    Sawyers, CL
    Paquette, RL
    O'Dwyer, ME
    BLOOD, 2002, 100 (02) : 435 - 441
  • [27] Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)
    T Fischer
    C Reifenrath
    GR Hess
    MT Corsetti
    S Kreil
    J Beck
    P Meinhardt
    G Beltrami
    B Schuch
    H Gschaidmeier
    R Hehlmann
    A Hochhaus
    A Carella
    C Huber
    Leukemia, 2002, 16 : 1220 - 1228
  • [28] STI571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response
    Hasserjian, RP
    Boecklin, F
    Parker, S
    Chase, A
    Dhar, S
    Zaiac, M
    Olavarria, E
    Lampert, I
    Henry, K
    Apperley, JF
    Goldman, JM
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 117 (03) : 360 - 367
  • [29] Characterization of the clinical response to STI-571: Biochemical evaluation of responsive and resistant advanced stage chronic myelogenous leukemia patients.
    Talpaz, M
    Donato, NJ
    Wu, JY
    Sah, NK
    Kantarjian, H
    BLOOD, 2000, 96 (11) : 735A - 735A
  • [30] Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Cortes, J
    Talpaz, M
    O'Brien, S
    Jones, D
    Luthra, R
    Shan, J
    Giles, F
    Faderl, S
    Verstovsek, S
    Garcia-Manero, G
    Rios, MB
    Kantarjian, H
    CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3425 - 3432
12345